KYMR — Kymera Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.83bn
- $1.31bn
- $78.59m
- 68
- 17
- 74
- 52
Annual cashflow statement for Kymera Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -41.2 | -45.6 | -100 | -155 | -147 |
| Depreciation | |||||
| Non-Cash Items | 1.64 | 7.09 | 30.8 | 36.4 | 37.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 56.7 | 125 | -61.9 | -37.6 | 2.68 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 17.9 | 88.1 | -129 | -153 | -103 |
| Capital Expenditures | -0.532 | -9.1 | -1.6 | -2.84 | -34.5 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -16 | -413 | -98.2 | 23.4 | 174 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -16.5 | -423 | -99.8 | 20.5 | 140 |
| Financing Cash Flow Items | — | 13.5 | 1.95 | 0 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 34.9 | 289 | 250 | 153 | 4.19 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 36.3 | -45.2 | 21.5 | 20.4 | 41.3 |